| Quality Management System | Documented pharmaceutical or research-grade quality system | Current quality manual, controlled SOPs, deviation records, CAPA procedures, change-control records, training records, and internal audit documentation.
Document controlCAPAAudit trail | Request a controlled sample of the quality documentation and verify that procedures apply to peptide synthesis, purification, testing, packaging, and release. |
| GMP Readiness | Manufacturing controls proportionate to the intended use | GMP certification or inspection history where applicable, batch records, material traceability, equipment qualification, environmental monitoring, and formal batch-release procedures.
GMPTraceabilityBatch release | Do not treat a marketing statement as proof of GMP status. Confirm the issuing authority, certificate scope, site address, validity period, and covered product category. |
| ISO Certification | Relevant certification for the supplied activity | ISO 9001 may support general quality management. ISO 13485 is relevant to manufacturers operating within medical-device quality systems. Certification should be site-specific and scope-specific.
ISO 9001ISO 13485 | Check the certificate number, accredited certification body, manufacturing site, scope of certification, and expiry date. ISO certification does not by itself prove peptide purity or clinical suitability. |
| Raw-Material Control | Qualified suppliers and identity testing for critical inputs | Approved-supplier list, incoming-material specifications, certificates of analysis, lot traceability, identity confirmation, and controls for amino acids, coupling reagents, solvents, resins, and other process materials.
Supplier qualificationIdentity testLot control | Confirm that the final peptide lot can be linked to the relevant raw-material lots and that critical materials are not accepted solely on the basis of supplier paperwork. |
| Peptide Synthesis | Validated or controlled solid-phase peptide synthesis process | Defined resin loading, coupling cycles, deprotection conditions, cleavage controls, process parameters, in-process checks, and documented handling of failed or reprocessed batches.
SPPSIn-process controlProcess validation | For complex or aggregation-prone sequences, request process-specific information, expected impurity profile, and evidence that scale-up does not materially reduce purity or recovery. |
| Purity Testing | Orthogonal analytical methods appropriate to the peptide | Reversed-phase HPLC or UPLC for purity assessment, together with mass spectrometry for molecular-mass confirmation. A single chromatographic peak should not be treated as complete identity proof.
RP-HPLCUPLCMS | Review chromatograms, integration parameters, system suitability results, sample concentration, column information, and acceptance criteria rather than relying only on a stated percentage. |
| Sequence Confirmation | Evidence supporting correct molecular identity and sequence | High-resolution mass spectrometry, MS/MS fragmentation where suitable, peptide mapping, amino-acid analysis, or other validated identity methods selected according to peptide structure.
HRMSMS/MSPeptide mapping | For modified peptides, verify the modification site, molecular formula, expected mass shift, stereochemistry requirements, and any conjugation or labeling information. |
| Impurity Profile | Characterization of process-related and product-related impurities | Data on deletion sequences, truncated peptides, oxidation products, deamidation products, residual protecting groups, aggregation, counter-ions, and residual solvents where relevant.
Related substancesResidual solventsAggregates | Ask whether reported purity is area percentage, mass percentage, or another calculation. Confirm that the specification matches the intended research application. |
| Residual Solvents | Risk-based control of organic solvents and volatile process residues | Gas chromatography or another suitable validated method, with limits established using applicable specifications such as ICH Q3C when relevant to the product use.
GCICH Q3C | Request the actual result for the supplied lot, not only a generic specification. Pay particular attention to solvents used during cleavage, purification, and lyophilization. |
| Water and Microbial Quality | Defined microbial-control strategy for the product format | Water-system monitoring where water is used in manufacturing, microbial limits testing where applicable, bioburden controls, and documented cleaning and sanitation procedures.
BioburdenWater systemSanitation | A non-sterile research peptide should not be represented as sterile. Verify the product classification, handling instructions, and storage conditions before laboratory use. |
| Endotoxin Control | Testing when the intended application requires endotoxin information | Bacterial endotoxin testing using a suitable method, such as an appropriate LAL or recombinant factor C procedure, with inhibition or enhancement controls and documented acceptance criteria.
BETLALrFC | Confirm whether the result is reported in EU per milligram, EU per vial, or another unit. Endotoxin testing does not establish sterility or freedom from all microbial contamination. |
| Sterility Assurance | Sterility claim supported by validated processes and testing | For products sold as sterile, review validated sterilization or aseptic-processing controls, environmental monitoring, sterility testing, container-closure controls, and relevant pharmacopeial methods.
Sterility testAseptic processContainer closure | Do not infer sterility from high HPLC purity, low endotoxin, or lyophilized presentation. Require explicit product labeling and supporting documentation. |
| Stability and Storage | Defined storage conditions and stability-indicating data | Accelerated or real-time stability information where available, freeze-thaw assessment when relevant, moisture and temperature controls, retest or expiry policy, and validated shipping conditions.
Stability studyCold chainRetest date | Confirm whether the product is supplied as a lyophilized solid or solution, whether light protection is required, and how temperature excursions are assessed during international transport. |
| Certificate of Analysis | Lot-specific CoA issued against defined specifications | Product identifier, batch number, manufacturing date, test methods, actual numerical results, specification limits, analyst or approval authorization, and document revision status.
Lot-specificActual resultsApproved CoA | Reject undated or generic CoAs that omit test methods, chromatograms, mass spectra, or actual batch results when those records are needed for qualification. |
| Reference Standards | Suitable reference materials for identity and assay testing | Qualification records for primary or secondary reference standards, assigned values, storage conditions, preparation records, and traceability to an appropriate source when available.
Reference standardAssigned valueTraceability | Determine whether the reference material is certified, qualified internally, or used only as a system-suitability material. These categories should not be treated as interchangeable. |
| Packaging and Labeling | Packaging that protects peptide quality during storage and transit | Moisture- and light-protective primary packaging where appropriate, tamper-evident or controlled packaging, batch labeling, net quantity, storage temperature, handling instructions, and hazard information.
Light protectionMoisture controlBatch label | Verify that the label, CoA, purchase order, and shipping documents use the same product name, sequence or identifier, batch number, quantity, and storage requirements. |
| Shipping Qualification | Transport conditions matched to peptide sensitivity | Qualified packaging configuration, temperature-monitoring approach where needed, documented courier or logistics controls, excursion procedures, and delivery-condition review.
Validated shipperTemperature loggerExcursion review | For temperature-sensitive products, request shipping validation or representative temperature data and define acceptance criteria before placing recurring orders. |
| Regulatory and Export Documentation | Complete documentation for the destination country and intended use | Commercial invoice, packing list, safety data sheet where applicable, harmonized tariff information, country-of-origin documentation, import permits where required, and non-clinical-use declaration.
SDSImport documentsNon-clinical use | Check local rules for biological materials, controlled substances, animal-derived components, genetically related materials, and products intended for human or veterinary use. |
| Supplier Auditability | Ability to support technical audits and corrective actions | Audit questionnaire responses, remote or onsite audit availability, quality agreement, complaint procedure, investigation timelines, recall or withdrawal process, and contact details for quality representatives.
Quality agreementComplaint handlingRecall readiness | Use auditability as a major differentiator for long-term sourcing. A low price should not compensate for missing records, unclear responsibility, or weak change notification. |
| Product Verification Before Purchase | Independent qualification of representative samples | Confirmatory testing by an independent laboratory may include HPLC or UPLC, mass spectrometry, water content, residual solvents, endotoxin, microbial testing, or other methods matched to the risk profile.
Independent testIncoming QCRisk-based testing | Use a written sampling plan and acceptance criteria. For recurring supply, periodically requalify the supplier and compare results across multiple lots. |
| Overall Buyer Decision | Evidence-based supplier qualification | Combine quality-system evidence, lot-specific analytical data, manufacturing-site verification, shipping performance, documentation accuracy, technical support, and total landed cost.
Risk-based scorecardMulti-lot reviewTotal cost | Prioritize verifiable quality and consistent documentation over headline purity or price alone. Define whether the product is for research, analytical, preclinical, or regulated manufacturing use before supplier selection. |
